Oscar Health (NYSE: OSCR) Q1 2026 profit jumps as revenue grows
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Oscar Health, Inc. reported strong results for the quarter ended March 31, 2026, and reaffirmed its full-year 2026 guidance. Total revenue reached $4.6 billion, up from $3.0 billion a year earlier, driven by higher membership and rate increases.
The medical loss ratio improved to 70.5% from 75.4%, and the SG&A expense ratio edged down to 15.2% from 15.8%, reflecting disciplined pricing and cost control. Earnings from operations were $704.1 million, with net income attributable to Oscar of $679.0 million, or $2.07 diluted EPS, versus $275.3 million, or $0.92, in 2025.
Adjusted EBITDA was $727.1 million, up from $328.8 million. Membership rose to 3.17 million from 2.04 million, entirely in Individual and Small Group offerings following the end of the Cigna+Oscar arrangement. Cash, cash equivalents and restricted cash increased to $4.83 billion as operating cash flow strengthened.
Positive
- Substantial profitability improvement: Net income attributable to Oscar Health, Inc. rose to $678.996 million and Adjusted EBITDA to $727.072 million for Q1 2026, both more than doubling versus the prior-year quarter.
- Better underwriting and cost metrics: Medical loss ratio improved to 70.5% from 75.4% and SG&A expense ratio declined to 15.2% from 15.8%, highlighting stronger unit economics.
- Stronger balance sheet and liquidity: Cash, cash equivalents and restricted cash and cash equivalents increased to $4.829 billion as of March 31, 2026, supported by $2.619 billion of cash provided by operating activities in Q1 2026.
- Solid membership growth: Total members increased to 3,174,489 as of March 31, 2026 from 2,039,467 a year earlier, all within Individual and Small Group offerings after ending the Cigna+Oscar arrangement.
Negative
- None.
Insights
Oscar delivers sharply higher Q1 profit, better margins, and reaffirms 2026 guidance.
Oscar Health posted Q1 2026 total revenue of $4.65B with net income attributable to the company of $679.0M. Earnings from operations more than doubled to $704.1M, and Adjusted EBITDA rose to $727.1M, indicating substantially improved profitability.
Underlying insurance performance strengthened: the medical loss ratio improved to 70.5% from 75.4%, while the SG&A expense ratio declined to 15.2%. Membership expanded to 3.17 million as of March 31, 2026, concentrated in Individual and Small Group plans after winding down the Cigna+Oscar partnership.
Operating cash flow reached $2.62B for Q1 2026, boosting cash, cash equivalents and restricted cash to $4.83B. Management reaffirmed its full-year 2026 outlook across all metrics and reiterated expectations for significantly expanded margins and meaningful profitability in 2026, while acknowledging standard industry and regulatory risks in its forward-looking statements.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total revenue: $4,647,194 thousand
Net income attributable to Oscar Health, Inc.: $678,996 thousand
Adjusted EBITDA: $727,072 thousand
+5 more
8 metrics
Total revenue
$4,647,194 thousand
Three months ended March 31, 2026
Net income attributable to Oscar Health, Inc.
$678,996 thousand
Three months ended March 31, 2026
Adjusted EBITDA
$727,072 thousand
Three months ended March 31, 2026
Medical loss ratio
70.5%
Three months ended March 31, 2026
SG&A expense ratio
15.2%
Three months ended March 31, 2026
Total members
3,174,489
As of March 31, 2026
Operating cash flow
$2,618,980 thousand
Net cash provided by operating activities, Q1 2026
Cash, cash equivalents and restricted cash
$4,829,250 thousand
As of March 31, 2026
Key Terms
Medical loss ratio, Adjusted EBITDA, risk adjustment, quota share reinsurance, +2 more
6 terms
Medical loss ratio financial
"The medical loss ratio was 70.5% for the first quarter of 2026 compared to 75.4%"
Medical loss ratio is the share of health insurance premiums that a plan spends on patient care and activities that improve care quality, rather than on administration, marketing, or profit. Think of it like a household budget showing how much of your paycheck goes to groceries versus overhead and discretionary items; a higher ratio means more money is going to care. For investors, the metric signals an insurer’s cost efficiency, pricing pressure and potential regulatory or rebate risk, all of which affect profitability and future cash flow.
Adjusted EBITDA financial
"Adjusted EBITDA was $727.1 million for the first quarter of 2026 compared to Adjusted EBITDA of $328.8 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
risk adjustment financial
"The increase was driven by higher membership and rate increases, partially offset by an increase in the net risk adjustment transfer accrual"
A statistical process that adjusts payments, performance measures or forecasts to account for differences in risk or baseline conditions across groups—most often used in health insurance and regulated businesses. It ensures that revenue, outcomes or profitability are compared on a level playing field, like giving students a test score that reflects their starting skill level, and matters to investors because it directly affects reported revenue, margins and regulatory incentives.
non-GAAP financial
"Adjusted EBITDA is a non-GAAP measure. See “Key Operating and Non-GAAP Financial Metrics"
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Earnings Snapshot
Total revenue: $4,647,194 thousand · Guidance included
Q1 2026
Total revenue
$4,647,194 thousand
Net income attributable to Oscar Health, Inc.
$678,996 thousand
Diluted EPS
$2.07
Adjusted EBITDA
$727,072 thousand
Medical loss ratio
70.5%
SG&A expense ratio
15.2%
Total members
3,174,489
Guidance
Oscar is reaffirming its full year 2026 outlook across all metrics as provided in its financial results press release dated February 10, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 6, 2026
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices) (Zip Code)
(646 ) 403-3677
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 6, 2026, Oscar Health, Inc. (the “Company”) announced the Company’s financial results for the quarter ended March 31, 2026. A copy of the press release issued in connection with the announcement is attached and furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The information in Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press Release, dated May 6, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Oscar Health, Inc. | |||||||||||
| By: | /s/ R. Scott Blackley | ||||||||||
| Name | R. Scott Blackley | ||||||||||
| Title: | Chief Financial Officer | ||||||||||
Date: May 6, 2026
 | |||||
Oscar Health, Inc. ir.hioscar.com News Release | |||||
Oscar Health Announces Strong Financial Results for First Quarter 2026 And Reaffirms 2026 Guidance
New York, NY, May 6, 2026 – Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR) announced today its financial results for the first quarter ended March 31, 2026.
“Oscar Health drove solid first-quarter performance with significant year-over-year improvements across our core metrics,” said Mark Bertolini, CEO of Oscar Health. “We are reaffirming our guidance and remain on track to significantly expand margins and achieve meaningful profitability in 2026. Consumers expect to shop for healthcare like everyday products – on choice, price, and value. Oscar’s exceptional technology, lifestyle products, and member experience deliver exactly that. The workforce is shifting, the individual market is resilient, and Oscar is leading the transition to a consumer-driven health economy.”
Oscar is reaffirming its full year 2026 outlook across all metrics as provided in its financial results press release dated February 10, 2026.
First Quarter 2026 Financial Highlights
| Three Months Ended March 31, | ||||||||||||||
| (in thousands, except percentages) | 2026 | 2025 | ||||||||||||
| Total revenue | $4,647,194 | $3,046,263 | ||||||||||||
| Medical loss ratio (“MLR”) | 70.5% | 75.4% | ||||||||||||
Selling, general, and administrative (“SG&A”) expense ratio | 15.2% | 15.8% | ||||||||||||
| Earnings from operations | $704,085 | $297,123 | ||||||||||||
| Net income attributable to Oscar Health, Inc. | $678,996 | $275,271 | ||||||||||||
Adjusted EBITDA(1) | $727,072 | $328,828 | ||||||||||||
| (1) Adjusted EBITDA is a non-GAAP measure. See “Key Operating and Non-GAAP Financial Metrics - Adjusted EBITDA” in this release for a reconciliation to net income, the most directly comparable GAAP measure, and for information regarding Oscar’s use of Adjusted EBITDA. | ||||||||||||||
| As of March 31, | ||||||||||||||
| Membership by Offering | 2026 | 2025 | ||||||||||||
Individual and Small Group (1) | 3,174,489 | 2,021,484 | ||||||||||||
Cigna+Oscar (2) | — | 17,983 | ||||||||||||
| Total Members | 3,174,489 | 2,039,467 | ||||||||||||
(1) 2025 membership includes small group members. The Company no longer offers small group plans effective December 15, 2024. | ||||||||||||||
(2) Represents total membership for our former co-branded partnership with Cigna. We did not renew the Cigna+Oscar Small Group arrangement after its initial term ended on December 31, 2024. | ||||||||||||||
1
Oscar Health, Inc.
News Release
First Quarter 2026 Key Metrics and Non-GAAP Financial Metrics
•Total revenue was approximately $4.6 billion for the first quarter of 2026 compared to $3.0 billion for the first quarter of 2025. The increase was driven by higher membership and rate increases, partially offset by an increase in the net risk adjustment transfer accrual.
•The medical loss ratio was 70.5% for the first quarter of 2026 compared to 75.4% for the first quarter of 2025. The decrease was primarily due to our disciplined pricing strategy, claims and risk adjustment seasonality from metal and new member mix, and favorable prior period reserve development. The Company had $68 million of favorable development in the first quarter of 2026 compared to $31 million of unfavorable development in the first quarter of 2025.
•The SG&A expense ratio was 15.2% for the first quarter of 2026 compared to 15.8% for the first quarter of 2025. The decrease was primarily due to greater fixed cost leverage and disciplined cost management, partially offset by the impact of higher risk adjustment as a percentage of premium.
•Earnings from operations was $704.1 million for the first quarter of 2026 compared to earnings from operations of $297.1 million for the first quarter of 2025. The significant increase reflects strong operating performance driven primarily by higher membership, rate increases, favorable prior period development, and fixed cost leverage.
•Net income attributable to Oscar Health, Inc. was $679.0 million, or $2.07 of diluted earnings per share, for the first quarter of 2026 compared to Net income attributable to Oscar Health, Inc. of $275.3 million, or $0.92 of diluted earnings per share, for the first quarter of 2025.
•Adjusted EBITDA was $727.1 million for the first quarter of 2026 compared to Adjusted EBITDA of $328.8 million for the first quarter of 2025.
2
Oscar Health, Inc.
News Release
Quarterly Conference Call Details
Oscar will host a conference call to discuss its financial results today, May 6, 2026, at 8:00 a.m. (ET). Investors and other interested parties are invited to listen to the conference call by dialing 1-855-761-5600 and entering the following conference ID: 7768132. A live audio webcast will also be available via the Investor Relations page of Oscar’s website at ir.hioscar.com. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
Non-GAAP Financial Information
This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release. For more information regarding Adjusted EBITDA, please see “Key Operating and Non-GAAP Financial Metrics” below.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our financial outlook and estimates, including Total revenue, Medical loss ratio, SG&A expense ratio, Earnings (loss) from operations, and other financial performance metrics, and the related underlying assumptions, our business and financial prospects, including management’s plans and objectives for future operations, expectations and business strategy, such as our 2026 margins and profitability, and industry and market dynamics and expected trends. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential,” or “continues” or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control.
Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our ability to execute our strategy and manage our growth effectively (including our ability to successfully integrate strategic acquisitions); our ability to retain and expand our member base; our ability to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs; unanticipated results of, or changes to, risk adjustment programs or our estimates thereof; evolving federal or state laws or regulations (including any changes in the interpretation or enforcement of existing laws and regulations), including changes with respect to the Patient Protection and Affordable Care Act and any regulations enacted thereunder, the expiration of the enhanced Advanced Premium Tax Credits, the implementation of new program integrity rules, the potential funding of a cost-sharing reduction program, or other government actions, such as the imposition of tariffs; our ability to achieve or maintain profitability in the future; our ability to arrange for the delivery of quality care and maintain good relations with brokers and the physicians, hospitals, and other providers within and outside our provider networks; our ability to comply with ongoing, complex and evolving regulatory requirements, including capital reserve and surplus requirements and applicable performance standards; changes or developments in the regulation of health insurance markets in the United States; our, or any of our vendors’, ability to comply with laws, regulations, and standards related to the handling of information about individuals or applicable consumer protection laws, including as a result of our participation in government-sponsored programs; the ability of our health insurance and Health Maintenance Organization subsidiaries to make payments of dividends or distributions to us, including to fund our business strategy; our ability to utilize quota share reinsurance to meet our capital and surplus requirements and protect against downside risk on medical claims; adverse market conditions resulting in our investment portfolio suffering losses or reducing our ability to meet our financing needs; unfavorable or otherwise costly outcomes of lawsuits, audits, investigations, and other third party claims that may arise from the extensive laws and regulations to which we are subject; incurrence of data security breaches of our or our partners’ information and technology systems; heightened competition in the markets in which we participate; our ability to attract and retain qualified personnel; uncertainties associated with our utilization of certain artificial intelligence (“AI”) and machine learning models; our ability to detect and prevent material weaknesses or significant control deficiencies in our internal controls over financial reporting or other failure to maintain an effective system of internal controls; adverse publicity or other adverse consequences related to our dual class structure or “controlled company” status; and the other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC.
3
Oscar Health, Inc.
News Release
You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.
About Oscar Health
Oscar Health, Inc. is a leading healthcare technology company built on a full-stack platform and a relentless focus on member experience. Oscar Health helps make high-quality and affordable care more accessible for millions of people through Oscar’s Individual & Family plans and ICHRA solutions, +Oscar technology services, and Lucie Health Marketplace. Consumers benefit from better choice, deeper engagement, and connection to high-value clinical care.
Investor Contact:
Chris Potochar
VP of Investor Relations
ir@hioscar.com
Media Contact:
Dalya Browne
Senior Director, External Communications
press@hioscar.com
Source: Oscar Health, Inc.
4
Oscar Health, Inc.
News Release
Oscar Health, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
| Three Months Ended March 31, | |||||||||||
| (in thousands, except per share amounts) | 2026 | 2025 | |||||||||
| Revenue | |||||||||||
| Premium | $ | 4,580,862 | $ | 2,995,821 | |||||||
| Investment income | 60,614 | 46,112 | |||||||||
| Other revenues | 5,718 | 4,330 | |||||||||
| Total revenue | 4,647,194 | 3,046,263 | |||||||||
| Operating Expenses | |||||||||||
| Medical | 3,229,857 | 2,259,651 | |||||||||
| Selling, general, and administrative | 706,234 | 482,759 | |||||||||
| Depreciation and amortization | 7,018 | 6,730 | |||||||||
| Total operating expenses | 3,943,109 | 2,749,140 | |||||||||
| Earnings from operations | 704,085 | 297,123 | |||||||||
| Interest expense | 5,383 | 5,994 | |||||||||
| Other expenses (income) | (71) | 2,918 | |||||||||
| Earnings before income taxes | 698,773 | 288,211 | |||||||||
| Income tax expense | 19,750 | 12,705 | |||||||||
| Net income | 679,023 | 275,506 | |||||||||
| Less: Net income attributable to noncontrolling interests | 27 | 235 | |||||||||
| Net income attributable to Oscar Health, Inc. | $ | 678,996 | $ | 275,271 | |||||||
| Earnings per Share | |||||||||||
| Basic | $ | 2.28 | $ | 1.10 | |||||||
| Diluted | $ | 2.07 | $ | 0.92 | |||||||
| Weighted Average Common Shares Outstanding | |||||||||||
| Basic | 298,184 | 251,279 | |||||||||
| Diluted | 329,751 | 305,938 | |||||||||
5
Oscar Health, Inc.
News Release
Oscar Health, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
| (in thousands, except per share amounts) | March 31, 2026 | December 31, 2025 | |||||||||
| Assets | |||||||||||
| Current Assets: | |||||||||||
| Cash and cash equivalents | $ | 4,805,139 | $ | 2,774,151 | |||||||
| Short-term investments | 1,994,644 | 1,216,461 | |||||||||
Accounts receivable (net of allowance for credit losses of $7,171 and $7,226) | 587,023 | 362,682 | |||||||||
Receivables from CMS (1) | 222,195 | 136,029 | |||||||||
| Reinsurance recoverable | 142,487 | 99,750 | |||||||||
| Other current assets | 25,817 | 24,331 | |||||||||
| Total current assets | 7,777,305 | 4,613,404 | |||||||||
| Property, equipment, and capitalized software, net | 94,194 | 88,350 | |||||||||
| Long-term investments | 1,266,775 | 1,470,987 | |||||||||
| Restricted deposits | 28,631 | 32,951 | |||||||||
| Other assets | 122,741 | 119,719 | |||||||||
| Total assets | $ | 9,289,646 | $ | 6,325,411 | |||||||
| Liabilities and Stockholders' Equity | |||||||||||
| Current Liabilities: | |||||||||||
| Benefits payable | $ | 1,734,051 | $ | 1,455,385 | |||||||
Payables to CMS (1) | 4,723,244 | 2,730,095 | |||||||||
| Accounts payable and other liabilities | 505,943 | 507,325 | |||||||||
| Unearned premiums | 172,004 | 166,203 | |||||||||
| Reinsurance payable | 5,112 | 3,579 | |||||||||
| Total current liabilities | 7,140,354 | 4,862,587 | |||||||||
| Long-term debt | 430,876 | 430,095 | |||||||||
| Other liabilities | 51,368 | 51,994 | |||||||||
| Total liabilities | 7,622,598 | 5,344,676 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders' Equity | |||||||||||
| Class A common stock ($0.00001 par value; 825,000 thousand shares authorized, 263,552 thousand and 261,851 thousand shares outstanding as of March 31, 2026 and December 31, 2025, respectively) | 3 | 3 | |||||||||
| Class B common stock ($0.00001 par value; 82,500 thousand shares authorized, 35,591 thousand and 35,838 thousand shares outstanding as of March 31, 2026 and December 31, 2025, respectively) | — | — | |||||||||
| Treasury stock (315 thousand shares as of March 31, 2026 and December 31, 2025) | (2,923) | (2,923) | |||||||||
| Additional paid-in capital | 4,277,292 | 4,256,972 | |||||||||
| Accumulated deficit | (2,615,438) | (3,294,434) | |||||||||
| Accumulated other comprehensive income | 5,000 | 18,030 | |||||||||
| Total Oscar Health, Inc. stockholders' equity | 1,663,934 | 977,648 | |||||||||
| Noncontrolling interests | 3,114 | 3,087 | |||||||||
| Total stockholders' equity | 1,667,048 | 980,735 | |||||||||
| Total liabilities and stockholders' equity | $ | 9,289,646 | $ | 6,325,411 | |||||||
(1) Centers for Medicare & Medicaid Services | |||||||||||
6
Oscar Health, Inc.
News Release
Oscar Health, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
| Three Months Ended March 31, | |||||||||||
| (in thousands) | 2026 | 2025 | |||||||||
Cash Flows from Operating Activities: | |||||||||||
| Net income | $ | 679,023 | $ | 275,506 | |||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||
Deferred taxes | (6,204) | 36 | |||||||||
Net realized gain on sale of financial instruments | (4) | (119) | |||||||||
Depreciation and amortization expense | 7,018 | 6,730 | |||||||||
| Amortization of debt issuance costs | 1,015 | 194 | |||||||||
Stock-based compensation expense | 15,969 | 24,975 | |||||||||
| Net accretion of investments | (7,077) | (7,673) | |||||||||
| Change in provision for credit losses | (55) | (8,650) | |||||||||
Changes in assets and liabilities: | |||||||||||
(Increase) / decrease in: | |||||||||||
Receivables from CMS (1) | (86,165) | (88,745) | |||||||||
| Accounts receivable | (224,288) | (97,827) | |||||||||
Reinsurance recoverable | (42,737) | 103,990 | |||||||||
Other assets | 5,344 | (13,265) | |||||||||
Increase / (decrease) in: | |||||||||||
Benefits payable | 278,666 | 108,848 | |||||||||
Payables to CMS (1) | 1,993,149 | 571,443 | |||||||||
Accounts payable and other liabilities | (2,007) | 24,294 | |||||||||
Unearned premiums | 5,800 | (3,492) | |||||||||
Reinsurance payable | 1,533 | (17,703) | |||||||||
| Net cash provided by operating activities | 2,618,980 | 878,542 | |||||||||
Cash Flows from Investing Activities: | |||||||||||
Purchase of investments | (914,842) | (336,869) | |||||||||
Sale of investments | 35,000 | 15,761 | |||||||||
Maturity and paydowns of investments | 299,243 | 155,906 | |||||||||
Purchase of property, equipment and capitalized software | (8,794) | (9,026) | |||||||||
Change in restricted deposits | (860) | — | |||||||||
Net cash used in investing activities | (590,253) | (174,228) | |||||||||
Cash Flows from Financing Activities: | |||||||||||
| Payments of debt issuance costs | (4,739) | — | |||||||||
| Tax payments related to net settlement of share-based awards | — | (855) | |||||||||
Proceeds from exercise of stock options | 1,139 | 5,728 | |||||||||
Net cash (used in) provided by financing activities | (3,600) | 4,873 | |||||||||
Increase in cash, cash equivalents and restricted cash equivalents | 2,025,127 | 709,187 | |||||||||
Cash, cash equivalents, restricted cash and cash equivalents—beginning of period | 2,804,123 | 1,551,118 | |||||||||
Cash, cash equivalents, restricted cash and cash equivalents—end of period | 4,829,250 | 2,260,305 | |||||||||
Cash and cash equivalents | 4,805,139 | 2,236,555 | |||||||||
Restricted cash and cash equivalents included in restricted deposits | 24,111 | 23,750 | |||||||||
Total cash, cash equivalents and restricted cash and cash equivalents | $ | 4,829,250 | $ | 2,260,305 | |||||||
| Supplemental Disclosures: | |||||||||||
| Interest payments | $ | 4,177 | $ | 154 | |||||||
| Income tax payments | $ | 44 | $ | — | |||||||
(1) Centers for Medicare & Medicaid Services | |||||||||||
7
Oscar Health, Inc.
News Release
Key Operating and Non-GAAP Financial Metrics
We regularly review the following key operating and Non-GAAP financial metrics, to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions. We believe these operational and financial measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.
Total Revenue
Total revenue includes premium revenue (net of risk adjustment transfers), investment income, and other revenues. We believe total revenue is an important metric to assess the growth of our business, as well as the earnings potential of our investment portfolio.
MLR
MLR is a metric used to calculate medical expenses as a percentage of net premiums before ceded quota share reinsurance. The impact of the federal risk adjustment program is included in the denominator of our MLR. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for healthcare of our members to the net premium before ceded quota share reinsurance.
| Three Months Ended March 31, | |||||||||||
| (in thousands, except percentages) | 2026 | 2025 | |||||||||
Net claims before ceded quota share reinsurance (A) | $ | 3,229,857 | $ | 2,259,651 | |||||||
Net premiums before ceded quota share reinsurance (B) | $ | 4,580,862 | $ | 2,995,821 | |||||||
Medical Loss Ratio (A divided by B) | 70.5 | % | 75.4 | % | |||||||
SG&A Expense Ratio
The SG&A expense ratio reflects the Company’s selling, general, and administrative expenses, as a percentage of total revenue (net of risk adjustment transfers). We believe the SG&A expense ratio is useful to evaluate our ability to manage our overall selling, general, and administrative cost base.
Earnings (Loss) from Operations
Earnings (loss) from operations is the Company's total revenue less total operating expenses. We believe earnings (loss) from operations is an important primary metric for assessing operating performance.
Net Income (Loss) Attributable to Oscar Health, Inc.
Net income (loss) attributable to Oscar Health, Inc. is net earnings (loss) allocated to the Company after net income (loss) attributable to noncontrolling interests. It is a key indicator of the Company’s profitability and operational efficiency, allowing management to evaluate performance and make informed decisions on strategic planning, cost management, and resource allocation.
8
Oscar Health, Inc.
News Release
Adjusted EBITDA
Adjusted EBITDA is defined as Net income (loss) for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), and depreciation and amortization, as further adjusted for stock-based compensation and other items that are considered unusual or not representative of underlying trends of our business, where applicable for the period presented. We present Adjusted EBITDA because we believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations. We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner.
By providing this non-GAAP financial measure, together with a reconciliation to the most comparable U.S. GAAP measure, Net income (loss), we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for, net income (loss) or other financial statement data presented in our Condensed Consolidated Financial Statements as indicators of financial performance.
| Three Months Ended March 31, | |||||||||||
| (in thousands) | 2026 | 2025 | |||||||||
| Net income | $ | 679,023 | $ | 275,506 | |||||||
Interest expense | 5,383 | 5,994 | |||||||||
| Other expenses (income) | (71) | 2,918 | |||||||||
Income tax expense | 19,750 | 12,705 | |||||||||
| Earnings from operations | 704,085 | 297,123 | |||||||||
Depreciation and amortization | 7,018 | 6,730 | |||||||||
Stock-based compensation(1) | 15,969 | 24,975 | |||||||||
| Adjusted EBITDA | $ | 727,072 | $ | 328,828 | |||||||
| (1) Represents non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number, and the valuation of awards. Additionally, these expenses are reported net of any stock-based compensation that has been capitalized for software development costs. | |||||||||||
9
Oscar Health, Inc.
News Release
Appendix
Oscar Health, Inc.
News Release
Supplemental Financial Information
Premium
The Company records premium revenue net of premiums for reinsurance contracts accounted for under reinsurance accounting. The following table reconciles total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total premium revenue in the Condensed Consolidated Statements of Operations:
| Three Months Ended March 31, | |||||||||||
| (in thousands) | 2026 | 2025 | |||||||||
| Direct policy premiums | $ | 6,030,275 | $ | 3,349,671 | |||||||
| Risk adjustment transfers | (1,442,811) | (373,749) | |||||||||
| Reinsurance premiums ceded | (5,618) | (2,542) | |||||||||
Assumed premiums (1) | (984) | 22,441 | |||||||||
| Premium | $ | 4,580,862 | $ | 2,995,821 | |||||||
(1) The Company did not renew the Cigna+Oscar Small Group arrangement with Cigna Health and Life Insurance Company after its initial term ended on December 31, 2024. Following termination, the Company has been providing transition and run-off services, and will continue to provide such services through December 31, 2026. The Company also continues to share in premiums and claims for plans sold or issued prior to December 15, 2024. | |||||||||||
Medical Expenses
The Company records medical expenses net of reinsurance recoveries for reinsurance contracts accounted for under reinsurance accounting. The following table reconciles total medical expenses to the amount presented in the Condensed Consolidated Statements of Operations:
| Three Months Ended March 31, | |||||||||||
| (in thousands) | 2026 | 2025 | |||||||||
| Direct claims incurred | $ | 3,293,837 | $ | 2,268,284 | |||||||
| Ceded reinsurance claims | (62,684) | (31,012) | |||||||||
| Assumed reinsurance claims | (1,296) | 22,379 | |||||||||
| Medical expenses | $ | 3,229,857 | $ | 2,259,651 | |||||||
Risk Adjustment
The risk adjustment programs in the markets the Company serves are administered federally by CMS and are designed to mitigate the potential impact of adverse selection and provide stability for health insurers. Under these programs, each plan is assigned a risk score based upon demographic information and current year claims information related to its members. Plans with lower than average risk scores generally pay into the pool, while plans with higher than average risk scores generally receive distributions. The following table provides a rollforward of the Company’s beginning and ending risk adjustment receivable and payable balances for the three months ended March 31, 2026 and 2025:
| Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 | ||||||||||||||||||||||||||||||||||
| (in thousands) | Risk Adjustment Receivable | Risk Adjustment Payable | Net Risk Adjustment Payable | Risk Adjustment Receivable | Risk Adjustment Payable | Net Risk Adjustment Payable | |||||||||||||||||||||||||||||
Beginning balance (1) | $ | 56,066 | $ | 2,587,700 | $ | 2,531,634 | $ | 64,779 | $ | 1,558,341 | $ | 1,493,562 | |||||||||||||||||||||||
| Change in accrual: | |||||||||||||||||||||||||||||||||||
| Current year | $ | 16,112 | $ | 1,374,310 | $ | 1,358,198 | $ | 25,666 | $ | 306,870 | $ | 281,204 | |||||||||||||||||||||||
Prior years (2) | 5,132 | 89,745 | 84,613 | (3,319) | 89,240 | 92,559 | |||||||||||||||||||||||||||||
| Change in accrual, net | $ | 21,244 | $ | 1,464,055 | $ | 1,442,811 | $ | 22,347 | $ | 396,110 | $ | 373,763 | |||||||||||||||||||||||
| Ending balance: | |||||||||||||||||||||||||||||||||||
| Current year | $ | 16,112 | $ | 1,374,310 | $ | 1,358,198 | $ | 25,666 | $ | 306,870 | $ | 281,204 | |||||||||||||||||||||||
| Prior years | 61,198 | 2,677,445 | 2,616,247 | 61,460 | 1,647,581 | 1,586,121 | |||||||||||||||||||||||||||||
| Ending balance | $ | 77,310 | $ | 4,051,755 | $ | 3,974,445 | $ | 87,126 | $ | 1,954,451 | $ | 1,867,325 | |||||||||||||||||||||||
| (1) The table includes risk adjustment data validation (“RADV”) receivables and payables. The balance at the beginning of each year presented pertains to prior policy years. | |||||||||||||||||||||||||||||||||||
| (2) Includes immaterial payments for prior policy years. | |||||||||||||||||||||||||||||||||||
FAQ
How did Oscar Health (OSCR) perform financially in Q1 2026?
Oscar Health delivered significantly stronger Q1 2026 results, with total revenue of $4.647 billion and net income attributable to Oscar of $678.996 million. Earnings from operations reached $704.085 million, and Adjusted EBITDA was $727.072 million, both well above Q1 2025 levels.
What happened to Oscar Health’s medical loss ratio in Q1 2026?
Oscar Health’s medical loss ratio improved to 70.5% in Q1 2026 from 75.4% a year earlier. Management attributes the decrease to disciplined pricing, claims and risk adjustment seasonality, favorable member mix, and $68 million of favorable prior-period reserve development versus $31 million of unfavorable development in Q1 2025.
Did Oscar Health (OSCR) reaffirm its 2026 outlook?
Yes. Oscar Health reaffirmed its full-year 2026 outlook across all metrics, consistent with guidance previously provided on February 10, 2026. The company stated it remains on track to significantly expand margins and achieve meaningful profitability in 2026, while acknowledging typical industry risks in its forward-looking statements.
How did membership change for Oscar Health in Q1 2026?
Total membership increased to 3,174,489 as of March 31, 2026 from 2,039,467 a year earlier. All members are now in Individual and Small Group offerings, as the company did not renew the Cigna+Oscar Small Group arrangement, which ended on December 31, 2024 and is now in run-off.
How strong was Oscar Health’s cash flow and liquidity in Q1 2026?
Oscar Health generated $2.618 billion of net cash provided by operating activities in Q1 2026. Cash, cash equivalents and restricted cash and cash equivalents totaled $4.829 billion at March 31, 2026, up from $2.260 billion one year earlier, supporting a stronger liquidity position.